Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model

Brian G. Choi, Gemma Vilahur, M. Urooj Zafar, Luis Cardoso, Daniel Yadegar, Borja Ibanez, James Tunstead, Juan Viles Gonzalez, Mitchell B. Schaffler, Valentin Fuster, Juan J. Badimon

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: Osteoporosis trials suggest raloxifene decreased cardiovascular events in women with pre-existing atherosclerosis. We assessed the hypothesis that selective estrogen receptor modulation induces plaque stability in "menopausal" animals. Methods and results: Atherosclerosis was induced in 42 ovariectomized New Zealand white rabbits by cholesterol feeding and mechanical injury. Animals were imaged by magnetic resonance imaging (MRI) for baseline atherosclerosis, and randomized to control (OVX (ovariectomized control group), n = 12), raloxifene 35-60 mg/kg/day by diet admixture (RLX (raloxifene therapy group), n = 24), or immediate sacrifice (n = 6) for immunohistopathologic correlation of MRI. Six months later, rabbits underwent repeat MRI then sacrifice for micro-computed tomography (μCT) and molecular analysis. Unlike OVX, RLX reduced atheroma volume. Analysis for lesion inflammation revealed reductions in COX-2 (cyclooxygenase-2), MMP-1 (matrix metalloproteinase-1), MCP-1 (monocyte chemoattractant protein-1) expression and macrophage infiltration in RLX versus OVX with concomitant upregulation of estrogen receptor α (ERα). μCT showed similar total vascular calcification between groups, but calcifications in RLX were less nodular with better radial organization (mean calcific arc angle 63 ± 7° versus 33 ± 6° in OVX), the predicted result of a 53% increase in BMP-2 (bone-morphogenetic protein-2). Conclusions: Raloxifene treatment results in reduced lesion volume, enhanced mechanical stability of vascular calcification, and less inflamed lesions characterized by less macrophage infiltration and reduced COX-2, MMP-1 and MCP-1 expression.

Original languageEnglish
Pages (from-to)76-84
Number of pages9
JournalAtherosclerosis
Volume201
Issue number1
DOIs
StatePublished - Nov 1 2008
Externally publishedYes

Fingerprint

Atherosclerotic Plaques
Menopause
Estrogen Receptors
Rabbits
Vascular Calcification
Atherosclerosis
Matrix Metalloproteinase 1
Chemokine CCL2
Magnetic Resonance Imaging
Cyclooxygenase 2
Macrophages
Tomography
Bone Morphogenetic Protein 2
Group Psychotherapy
Osteoporosis
Up-Regulation
Cholesterol
Diet
Inflammation
Control Groups

Keywords

  • Atherosclerosis
  • Inflammation
  • Osteoporosis
  • Selective estrogen receptor modulator (SERM)
  • Vascular calcification

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Choi, B. G., Vilahur, G., Zafar, M. U., Cardoso, L., Yadegar, D., Ibanez, B., ... Badimon, J. J. (2008). Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model. Atherosclerosis, 201(1), 76-84. https://doi.org/10.1016/j.atherosclerosis.2008.01.017

Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model. / Choi, Brian G.; Vilahur, Gemma; Zafar, M. Urooj; Cardoso, Luis; Yadegar, Daniel; Ibanez, Borja; Tunstead, James; Viles Gonzalez, Juan; Schaffler, Mitchell B.; Fuster, Valentin; Badimon, Juan J.

In: Atherosclerosis, Vol. 201, No. 1, 01.11.2008, p. 76-84.

Research output: Contribution to journalArticle

Choi, BG, Vilahur, G, Zafar, MU, Cardoso, L, Yadegar, D, Ibanez, B, Tunstead, J, Viles Gonzalez, J, Schaffler, MB, Fuster, V & Badimon, JJ 2008, 'Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model', Atherosclerosis, vol. 201, no. 1, pp. 76-84. https://doi.org/10.1016/j.atherosclerosis.2008.01.017
Choi, Brian G. ; Vilahur, Gemma ; Zafar, M. Urooj ; Cardoso, Luis ; Yadegar, Daniel ; Ibanez, Borja ; Tunstead, James ; Viles Gonzalez, Juan ; Schaffler, Mitchell B. ; Fuster, Valentin ; Badimon, Juan J. / Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model. In: Atherosclerosis. 2008 ; Vol. 201, No. 1. pp. 76-84.
@article{e71c9d974f6f44e39d971953c8867511,
title = "Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model",
abstract = "Objective: Osteoporosis trials suggest raloxifene decreased cardiovascular events in women with pre-existing atherosclerosis. We assessed the hypothesis that selective estrogen receptor modulation induces plaque stability in {"}menopausal{"} animals. Methods and results: Atherosclerosis was induced in 42 ovariectomized New Zealand white rabbits by cholesterol feeding and mechanical injury. Animals were imaged by magnetic resonance imaging (MRI) for baseline atherosclerosis, and randomized to control (OVX (ovariectomized control group), n = 12), raloxifene 35-60 mg/kg/day by diet admixture (RLX (raloxifene therapy group), n = 24), or immediate sacrifice (n = 6) for immunohistopathologic correlation of MRI. Six months later, rabbits underwent repeat MRI then sacrifice for micro-computed tomography (μCT) and molecular analysis. Unlike OVX, RLX reduced atheroma volume. Analysis for lesion inflammation revealed reductions in COX-2 (cyclooxygenase-2), MMP-1 (matrix metalloproteinase-1), MCP-1 (monocyte chemoattractant protein-1) expression and macrophage infiltration in RLX versus OVX with concomitant upregulation of estrogen receptor α (ERα). μCT showed similar total vascular calcification between groups, but calcifications in RLX were less nodular with better radial organization (mean calcific arc angle 63 ± 7° versus 33 ± 6° in OVX), the predicted result of a 53{\%} increase in BMP-2 (bone-morphogenetic protein-2). Conclusions: Raloxifene treatment results in reduced lesion volume, enhanced mechanical stability of vascular calcification, and less inflamed lesions characterized by less macrophage infiltration and reduced COX-2, MMP-1 and MCP-1 expression.",
keywords = "Atherosclerosis, Inflammation, Osteoporosis, Selective estrogen receptor modulator (SERM), Vascular calcification",
author = "Choi, {Brian G.} and Gemma Vilahur and Zafar, {M. Urooj} and Luis Cardoso and Daniel Yadegar and Borja Ibanez and James Tunstead and {Viles Gonzalez}, Juan and Schaffler, {Mitchell B.} and Valentin Fuster and Badimon, {Juan J.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1016/j.atherosclerosis.2008.01.017",
language = "English",
volume = "201",
pages = "76--84",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model

AU - Choi, Brian G.

AU - Vilahur, Gemma

AU - Zafar, M. Urooj

AU - Cardoso, Luis

AU - Yadegar, Daniel

AU - Ibanez, Borja

AU - Tunstead, James

AU - Viles Gonzalez, Juan

AU - Schaffler, Mitchell B.

AU - Fuster, Valentin

AU - Badimon, Juan J.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Objective: Osteoporosis trials suggest raloxifene decreased cardiovascular events in women with pre-existing atherosclerosis. We assessed the hypothesis that selective estrogen receptor modulation induces plaque stability in "menopausal" animals. Methods and results: Atherosclerosis was induced in 42 ovariectomized New Zealand white rabbits by cholesterol feeding and mechanical injury. Animals were imaged by magnetic resonance imaging (MRI) for baseline atherosclerosis, and randomized to control (OVX (ovariectomized control group), n = 12), raloxifene 35-60 mg/kg/day by diet admixture (RLX (raloxifene therapy group), n = 24), or immediate sacrifice (n = 6) for immunohistopathologic correlation of MRI. Six months later, rabbits underwent repeat MRI then sacrifice for micro-computed tomography (μCT) and molecular analysis. Unlike OVX, RLX reduced atheroma volume. Analysis for lesion inflammation revealed reductions in COX-2 (cyclooxygenase-2), MMP-1 (matrix metalloproteinase-1), MCP-1 (monocyte chemoattractant protein-1) expression and macrophage infiltration in RLX versus OVX with concomitant upregulation of estrogen receptor α (ERα). μCT showed similar total vascular calcification between groups, but calcifications in RLX were less nodular with better radial organization (mean calcific arc angle 63 ± 7° versus 33 ± 6° in OVX), the predicted result of a 53% increase in BMP-2 (bone-morphogenetic protein-2). Conclusions: Raloxifene treatment results in reduced lesion volume, enhanced mechanical stability of vascular calcification, and less inflamed lesions characterized by less macrophage infiltration and reduced COX-2, MMP-1 and MCP-1 expression.

AB - Objective: Osteoporosis trials suggest raloxifene decreased cardiovascular events in women with pre-existing atherosclerosis. We assessed the hypothesis that selective estrogen receptor modulation induces plaque stability in "menopausal" animals. Methods and results: Atherosclerosis was induced in 42 ovariectomized New Zealand white rabbits by cholesterol feeding and mechanical injury. Animals were imaged by magnetic resonance imaging (MRI) for baseline atherosclerosis, and randomized to control (OVX (ovariectomized control group), n = 12), raloxifene 35-60 mg/kg/day by diet admixture (RLX (raloxifene therapy group), n = 24), or immediate sacrifice (n = 6) for immunohistopathologic correlation of MRI. Six months later, rabbits underwent repeat MRI then sacrifice for micro-computed tomography (μCT) and molecular analysis. Unlike OVX, RLX reduced atheroma volume. Analysis for lesion inflammation revealed reductions in COX-2 (cyclooxygenase-2), MMP-1 (matrix metalloproteinase-1), MCP-1 (monocyte chemoattractant protein-1) expression and macrophage infiltration in RLX versus OVX with concomitant upregulation of estrogen receptor α (ERα). μCT showed similar total vascular calcification between groups, but calcifications in RLX were less nodular with better radial organization (mean calcific arc angle 63 ± 7° versus 33 ± 6° in OVX), the predicted result of a 53% increase in BMP-2 (bone-morphogenetic protein-2). Conclusions: Raloxifene treatment results in reduced lesion volume, enhanced mechanical stability of vascular calcification, and less inflamed lesions characterized by less macrophage infiltration and reduced COX-2, MMP-1 and MCP-1 expression.

KW - Atherosclerosis

KW - Inflammation

KW - Osteoporosis

KW - Selective estrogen receptor modulator (SERM)

KW - Vascular calcification

UR - http://www.scopus.com/inward/record.url?scp=53849129582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53849129582&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2008.01.017

DO - 10.1016/j.atherosclerosis.2008.01.017

M3 - Article

C2 - 18367192

AN - SCOPUS:53849129582

VL - 201

SP - 76

EP - 84

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -